SG11201704628VA - Macrocyclic compounds as irak1/4 inhibitors and uses thereof - Google Patents
Macrocyclic compounds as irak1/4 inhibitors and uses thereofInfo
- Publication number
- SG11201704628VA SG11201704628VA SG11201704628VA SG11201704628VA SG11201704628VA SG 11201704628V A SG11201704628V A SG 11201704628VA SG 11201704628V A SG11201704628V A SG 11201704628VA SG 11201704628V A SG11201704628V A SG 11201704628VA SG 11201704628V A SG11201704628V A SG 11201704628VA
- Authority
- SG
- Singapore
- Prior art keywords
- irak1
- inhibitors
- macrocyclic compounds
- macrocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562112374P | 2015-02-05 | 2015-02-05 | |
| PCT/US2016/016709 WO2016127025A1 (en) | 2015-02-05 | 2016-02-05 | Macrocyclic compounds as irak1/4 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201704628VA true SG11201704628VA (en) | 2017-07-28 |
Family
ID=55436167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201704628VA SG11201704628VA (en) | 2015-02-05 | 2016-02-05 | Macrocyclic compounds as irak1/4 inhibitors and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9708324B2 (de) |
| EP (1) | EP3253764B1 (de) |
| JP (1) | JP6835727B2 (de) |
| KR (1) | KR20170109546A (de) |
| CN (1) | CN107849055B (de) |
| AU (1) | AU2016215185B2 (de) |
| BR (1) | BR112017013677B1 (de) |
| CA (1) | CA2970534C (de) |
| ES (1) | ES2886577T3 (de) |
| IL (1) | IL253520B (de) |
| MX (1) | MX2017009625A (de) |
| NZ (1) | NZ732538A (de) |
| RU (1) | RU2730016C2 (de) |
| SG (1) | SG11201704628VA (de) |
| WO (1) | WO2016127025A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3273966B1 (de) | 2015-03-27 | 2023-05-03 | Dana-Farber Cancer Institute, Inc. | Hemmer von cyclinabhängigen kinasen |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| WO2020005807A1 (en) * | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| CN113194928A (zh) | 2018-07-31 | 2021-07-30 | 罗索肿瘤学公司 | (s)-5-氨基-3-(4-((5-氟-2-甲氧基苯甲酰胺基)甲基)苯基)-1-(1,1,1-三氟丙-2-基)-1h-吡唑-4-甲酰胺的喷雾干燥的分散体和制剂 |
| CR20210495A (es) * | 2019-03-28 | 2021-10-18 | Lupin Ltd | Compuestos macrocíclicos como agonistas de sting |
| CN111603471B (zh) * | 2020-06-24 | 2021-07-09 | 山东省科学院生物研究所 | 一种邻二氮杂环化合物在制备抑制tlr4受体的药物中的用途 |
| US20230295146A1 (en) * | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| WO2022070287A1 (ja) * | 2020-09-30 | 2022-04-07 | 旭化成ファーマ株式会社 | マクロサイクル化合物 |
| WO2024030908A1 (en) * | 2022-08-01 | 2024-02-08 | Children's Hospital Medical Center | Multi-cyclic irak1 and irak4 inhibiting compounds and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008520670A (ja) * | 2004-11-17 | 2008-06-19 | メルク エンド カムパニー インコーポレーテッド | アルツハイマー病の治療のための大環状第三アミンβ−セクレターゼ阻害剤 |
| MY169441A (en) * | 2004-12-08 | 2019-04-11 | Janssen Pharmaceutica Nv | 2,4, (4,6) pyrimidine derivatives |
| US8933066B2 (en) * | 2011-04-14 | 2015-01-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| WO2014058691A1 (en) * | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| WO2014121942A1 (en) * | 2013-02-07 | 2014-08-14 | Merck Patent Gmbh | Macrocyclic pyridazinone derivatives |
| EP2970334B1 (de) * | 2013-03-15 | 2018-05-23 | Biogen MA Inc. | Makrocyclische verbindungen als irak4-hemmer für die behandlung von entzündlichen erkrankungen |
-
2016
- 2016-02-05 US US15/016,569 patent/US9708324B2/en active Active
- 2016-02-05 ES ES16706472T patent/ES2886577T3/es active Active
- 2016-02-05 WO PCT/US2016/016709 patent/WO2016127025A1/en active Application Filing
- 2016-02-05 CN CN201680018713.8A patent/CN107849055B/zh active Active
- 2016-02-05 CA CA2970534A patent/CA2970534C/en active Active
- 2016-02-05 RU RU2017130762A patent/RU2730016C2/ru active
- 2016-02-05 BR BR112017013677-5A patent/BR112017013677B1/pt active IP Right Grant
- 2016-02-05 AU AU2016215185A patent/AU2016215185B2/en not_active Ceased
- 2016-02-05 SG SG11201704628VA patent/SG11201704628VA/en unknown
- 2016-02-05 KR KR1020177020263A patent/KR20170109546A/ko not_active Application Discontinuation
- 2016-02-05 EP EP16706472.4A patent/EP3253764B1/de active Active
- 2016-02-05 MX MX2017009625A patent/MX2017009625A/es unknown
- 2016-02-05 JP JP2017540605A patent/JP6835727B2/ja not_active Expired - Fee Related
- 2016-02-05 NZ NZ732538A patent/NZ732538A/en not_active IP Right Cessation
-
2017
- 2017-06-12 US US15/620,049 patent/US9815836B2/en active Active
- 2017-07-17 IL IL253520A patent/IL253520B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN107849055B (zh) | 2020-08-07 |
| US20170275284A1 (en) | 2017-09-28 |
| AU2016215185A1 (en) | 2017-06-29 |
| CN107849055A (zh) | 2018-03-27 |
| ES2886577T3 (es) | 2021-12-20 |
| BR112017013677B1 (pt) | 2023-11-21 |
| WO2016127025A1 (en) | 2016-08-11 |
| EP3253764A1 (de) | 2017-12-13 |
| RU2017130762A3 (de) | 2019-04-30 |
| NZ732538A (en) | 2022-04-29 |
| US9815836B2 (en) | 2017-11-14 |
| EP3253764B1 (de) | 2021-06-09 |
| RU2017130762A (ru) | 2019-03-05 |
| RU2730016C2 (ru) | 2020-08-14 |
| US20160229856A1 (en) | 2016-08-11 |
| CA2970534C (en) | 2023-08-29 |
| MX2017009625A (es) | 2017-11-20 |
| CA2970534A1 (en) | 2016-08-11 |
| AU2016215185B2 (en) | 2020-06-25 |
| KR20170109546A (ko) | 2017-09-29 |
| IL253520A0 (en) | 2017-09-28 |
| US9708324B2 (en) | 2017-07-18 |
| JP6835727B2 (ja) | 2021-02-24 |
| IL253520B (en) | 2020-07-30 |
| JP2018506531A (ja) | 2018-03-08 |
| BR112017013677A2 (pt) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255102A1 (zh) | 雜環化合物及其應用 | |
| SG11201704628VA (en) | Macrocyclic compounds as irak1/4 inhibitors and uses thereof | |
| HK1249101A1 (zh) | 作為magl抑制劑的1，1，1-三氟-3-羥基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羥基丁-2-基氨基甲酸酯衍生物 | |
| HK1247614A1 (zh) | 治療化合物及其用途 | |
| HK1232137A1 (zh) | 治療化合物和組合物 | |
| LT3102555T (lt) | Junginių kompozicijos ir jų panaudojimas | |
| SG11201708027XA (en) | Compounds and their use as bace1 inhibitors | |
| IL264446A (en) | Compounds and compositions and their use | |
| HK1247788A1 (zh) | 殺真菌化合物和組合物 | |
| SG11201706029VA (en) | Anti-senescence compounds and uses thereof | |
| HK1246780A1 (zh) | 氮雜-吡啶酮化合物及其用途 | |
| HK1248697A1 (zh) | 治療化合物及其用途 | |
| HK1257539A1 (zh) | 新的化合物及其用途 | |
| ZA201802256B (en) | Compounds and therapeutic uses thereof | |
| ZA201705456B (en) | Benzoxaborole compounds and uses thereof | |
| GB201504763D0 (en) | Compounds and uses | |
| GB201616439D0 (en) | Compounds and uses | |
| PT3202759T (pt) | Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo | |
| IL264445A (en) | Compounds and compositions and their use | |
| GB201507753D0 (en) | New compounds and uses | |
| IL253459A0 (en) | Isoergoline compounds and their uses | |
| GB201718875D0 (en) | Autophagy-inhibiting compounds and uses thereof | |
| GB201614961D0 (en) | Compounds and compositions for use | |
| GB201614224D0 (en) | Compounds and uses thereof | |
| IL258458B (en) | Peroxyhemiacetal profragrant and proflavor compounds |